Merck price target raised to $140 from $135 at Wells Fargo

Wells Fargo raised the firm’s price target on Merck to $140 from $135 and keeps an Equal Weight rating on the shares. Wells believes Merck needs more than just a Keytruda beat and raise to work, and Q1 results delivered just that with Vaxneuvance strength and positive color on Winrevair access, the analyst tells investors in a research note.